Alteration of liver parameters in non-alcoholic fatty liver disease in patients with metabolic syndrome
DOI:
https://doi.org/10.19230/10.19230/jonnpr.2016.1.1.929Keywords:
Liver steatosis, Cardiovascular risk, Altered transaminases, Non-alcoholic fatty liver disease (NAFLD)Abstract
The interest of non-alcoholic fatty liver disease (NAFLD) is growing due to several reasons: high prevalence of the disease in the Western World, its capability to progress towards more aggressive histological forms and its association with diseases that increase
cardiovascular risk.
Objective: To analyze the alteration of liver parameters in NAFLD in patients with metabolic syndrome.
Methods: A transverse, descriptive study of 100 patients with two or more cardiovascular risk factors was conducted. All patients signed informed consent. Patients selected were among those attending our Medical Office of Primary Attention and who had very little or no alcoholic consumption. A complete battery of analysis was performed including total abdominal ultrasound. Steatosis was evaluated and, if determined positive, patients were stratified in three degrees. The following determinations were collected: sex, personal and familial history of diabetes, arterial hypertension, dyslipidemia, age, weight, BMI, present pharmacological treatment, analytical parameters, blood pressure and abdominal perimeter.
Results: 100 patients were included in the study, 56 (56%) women and 44 (44%) men, with an average age of 61,84 + 9,5 years 23% of all patients did not have NAFLD; 29% had mild NAFLD, 29% had moderate NAFLD and 19% had severe NAFLD. 82% of men presented NAFLD. 29% of women did not nave NAFLD. 22% were overweight and 38% were obese. Blood pressure was altered in 22% of men and 18% of women. 60% had altered fasting blood glucose. 36% had hypertriglyceridemia, 41% hypercholesterolemia with 65% high LDL cholesterol and 16% of low HDL cholesterol. 83% of patients had two or more criteria of metabolic syndrome. Average transaminases were: ALT 24.98 u/i; AST 32.19 u/i; GGT 55,65 u/i; ALT/AST ratio: 0.77. Lactate dehydrogenase 255.30 u/L. Alkaline phosphatase 82.80 u/L and bilirubin 0.78 mg/dL
Conclusions: We did not find correlation between liver steatosis and alteration of liver parameters in our study.
Downloads
References
Ludwig J, Viggiano TR, McGuill DB, Ott BGJ. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hither
to unnamed disease. Mayo Clinic Proc. 1980;55:434-8.
Bedogni G, Miglioli L, Masutti F,Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for
nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study. Hepatology. 2005;42:44-52.
Bellentani S, Tiribelli C, Sacciccio G, Sodde M, Fratti M, De Martin C, et al and the Dionysos Study Group.
Prevalence of chronic liver disease in the general population of Northern Italy: The Dionysos Study. Hepatology.
;20:1442-9.
Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for
hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112-7.
Parés A, Tresserras R, Núñez I, Cerralbo M, Plana P, Pujol FJ, et al. Prevalencia y factores asociados a la
presencia de esteatosis hepática en varones adultos aparentemente sanos. Med Clin (Barc). 2000;114:561-5.
Martín-Domínguez V, González-Casas R, Mendoza-Jiménez -Ridruejo J, et al. Etiopatogenia, diagnóstico y
tratamiento de la enfermedad del hígado graso no alcohólico. Revista española de enfermedades digestivas.
;105(7):409-420.
Milié S, Lulié D, Stimac D. Non alcoholic fatty liver disease and obesity: biomechical, metabolic an clinical
presentations. World J Gastroenterol 2014;20(28): 9330-9337.
Alves de Carvalho, Mª do S. et al. Risk factors associated with hepatic steatosis: a study in patients in the
Northeast Brazil. Nutr Hosp 2012;27(4):1344-1350.
Loureiro, Carolina et al. Esteatosis Hepática: ¿preludio de diabetes tipo 2 en población pediátrica? Nutr Hosp.
;29(2):350-358.
X. Buqué, P. Aspichueta y B. Ochoa. Fundamento molecular de la esteatosis hepática asociada a la obesidad.
Rev Esp Enferm Dig 2008;100(9):565-68.
Powell EE, Cooksley WGE, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study
of forty–two patients for up to 21 years. Hepatology 1990; 11: 74-80.
Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, et al. Prevalence and risk factors of non-alcoholic fatty liver
disease in potential living liver donors in Korea: A review of 589 consecutive liver biopsies in a single center. J
Hepatol. 2007;47:239-44.
Reid AR. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710-23.
Adams LA, Talwalkar JA. Diagnostic evaluation of non-alcoholic fatty liver disease. J Clin Gastroenterol.
;40:S34-8.
Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United
States. Am J Gastroenterol. 2003;98:960-7.
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
